三阴性乳腺癌的腔面雄激素受体（LAR）亚型：分子、形态和临床特征。
Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
机构信息
Department of Pathology, Siberian State Medical University Ministry of Health of Russia, Tomsk 634050, Russia.
Department of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634009, Russia.
出版信息
J Zhejiang Univ Sci B. 2022 Aug 15;23(8):617-624. doi: 10.1631/jzus.B2200113.
Abstract
According to the classification presented by Lehmann BD (2016), triple-negative breast cancer (TNBC) is a heterogeneous group of malignant tumors with four specific subtypes: basal-like (subtype 1 and subtype 2), mesenchymal, and luminal androgen receptor (LAR) subtypes. The basal-like subtypes of carcinomas predominate in this group, accounting for up to 80% of all cases. Despite the significantly lower proportions of mesenchymal and LAR variants in the group of breast carcinomas with a TNBC profile, such tumors are characterized by aggressive biological behavior. To this end, the LAR subtype is of particular interest, since the literature on such tumors presents different and even contradictory data concerning the disease course and prognosis. This review is devoted to the analysis of the relevant literature, reflecting the main results of studies on the molecular properties and clinical features of the disease course of LAR-type TNBC carcinomas.
摘要
根据 Lehmann BD（2016）提出的分类，三阴性乳腺癌（TNBC）是一组具有四种特定亚型的恶性肿瘤：基底样（亚型 1 和亚型 2）、间充质和腔面雄激素受体（LAR）亚型。在该组中，基底样癌亚型占主导地位，占所有病例的高达 80%。尽管在 TNBC 特征的乳腺癌组中，间充质和 LAR 变体的比例明显较低，但此类肿瘤的生物学行为具有侵袭性。为此，LAR 亚型特别有趣，因为有关此类肿瘤的文献提供了关于疾病过程和预后的不同甚至相互矛盾的数据。本综述致力于分析相关文献，反映了关于 LAR 型 TNBC 癌的分子特性和疾病过程临床特征的主要研究结果。
相似文献
1
Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.三阴性乳腺癌的腔面雄激素受体（LAR）亚型：分子、形态和临床特征。
J Zhejiang Univ Sci B. 2022 Aug 15;23(8):617-624. doi: 10.1631/jzus.B2200113.
2
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.在恩扎卢胺耐药的腔面雄激素受体三阴性乳腺癌患者来源异种移植模型中对 mTOR 和 PI3K 抑制剂的反应。
Theranostics. 2020 Jan 1;10(4):1531-1543. doi: 10.7150/thno.36182. eCollection 2020.
3
Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.雄激素受体和 FOXA1 的共表达定义了一种“腔面雄激素受体”的猫乳腺肿瘤亚型，这是乳腺癌的自发模型。
BMC Cancer. 2019 Dec 30;19(1):1267. doi: 10.1186/s12885-019-6483-6.
4
Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.三阴性乳腺癌的多种分子亚型严重依赖雄激素受体，并在体内对恩杂鲁胺有反应。
Mol Cancer Ther. 2015 Mar;14(3):769-78. doi: 10.1158/1535-7163.MCT-14-0926. Epub 2015 Feb 23.
5
Imaging features of triple-negative breast cancers according to androgen receptor status.三阴性乳腺癌根据雄激素受体状态的影像学特征。
Eur J Radiol. 2019 May;114:167-174. doi: 10.1016/j.ejrad.2019.03.017. Epub 2019 Mar 21.
6
Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification.基于三阴性乳腺癌分子分型的腔面雄激素受体亚型和肿瘤浸润淋巴细胞组。
Sci Rep. 2024 May 17;14(1):11278. doi: 10.1038/s41598-024-61640-z.
7
Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype.鉴定一种可靶向的 JAK-STAT 富集的雄激素受体和雄激素受体剪接变异阳性的三阴性乳腺癌亚型。
Cell Rep. 2023 Dec 26;42(12):113461. doi: 10.1016/j.celrep.2023.113461. Epub 2023 Nov 17.
8
A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.三阴性乳腺癌替代亚型分类与基因表达亚型相关。
Breast Cancer Res Treat. 2022 Feb;191(3):599-610. doi: 10.1007/s10549-021-06437-8. Epub 2022 Jan 12.
9
Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer.三阴性乳腺癌的异质性临床影像学表现。
Anticancer Res. 2020 Apr;40(4):2125-2131. doi: 10.21873/anticanres.14171.
10
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.三阴性乳腺癌中的雄激素受体：无靶点亚型的潜在靶点。
Cancer Treat Rev. 2018 Jul;68:102-110. doi: 10.1016/j.ctrv.2018.06.005. Epub 2018 Jun 11.
引用本文的文献
1
Targeting Mitochondrial Quality Control for the Treatment of Triple-Negative Breast Cancer: From Molecular Mechanisms to Precision Therapy.靶向线粒体质量控制用于三阴性乳腺癌治疗：从分子机制到精准治疗
Biomolecules. 2025 Jul 5;15(7):970. doi: 10.3390/biom15070970.
2
Quantitative proteomics analysis of triple-negative breast cancers.三阴性乳腺癌的定量蛋白质组学分析
NPJ Precis Oncol. 2025 Apr 24;9(1):117. doi: 10.1038/s41698-025-00907-8.
3
Iron-Dependent Cell Death: Exploring Ferroptosis as a Unique Target in Triple-Negative Breast Cancer Management.铁依赖性细胞死亡：探索铁死亡作为三阴性乳腺癌治疗的独特靶点
Cancer Manag Res. 2025 Mar 19;17:625-637. doi: 10.2147/CMAR.S503932. eCollection 2025.
4
Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations.雄激素受体阳性三阴性乳腺癌的新辅助化疗反应：潜在的预测生物标志物和基因改变
Breast Cancer Res. 2025 Mar 20;27(1):41. doi: 10.1186/s13058-025-01994-y.
5
LncRNA-MALAT1 promotes triple-negative breast cancer progression and function as ceRNA to target REEP5 by sponging miR-106a-5p.长链非编码RNA-MALAT1促进三阴性乳腺癌进展，并作为竞争性内源RNA通过海绵吸附miR-106a-5p靶向REEP5发挥作用。
Eur J Med Res. 2025 Mar 10;30(1):159. doi: 10.1186/s40001-025-02420-x.
6
Classifications of triple-negative breast cancer: insights and current therapeutic approaches.三阴性乳腺癌的分类：见解与当前治疗方法
Cell Biosci. 2025 Feb 1;15(1):13. doi: 10.1186/s13578-025-01359-0.
7
Single-cell transcriptional atlas of human breast cancers and model systems.人类乳腺癌及模型系统的单细胞转录组图谱。
Clin Transl Med. 2024 Oct;14(10):e70044. doi: 10.1002/ctm2.70044.
8
Roles of lncRNA in the diagnosis and prognosis of triple-negative breast cancer.长链非编码 RNA 在三阴性乳腺癌诊断和预后中的作用。
J Zhejiang Univ Sci B. 2023 Dec 15;24(12):1123-1140. doi: 10.1631/jzus.B2300067.
9
Advantages of contrast-enhanced ultrasound in the localization and diagnostics of sentinel lymph nodes in breast cancer.超声造影在乳腺癌前哨淋巴结定位及诊断中的优势。
J Zhejiang Univ Sci B. 2023 Nov 15;24(11):985-997. doi: 10.1631/jzus.B2300019.
10
Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.基于三阴性乳腺癌亚型的 B7-H4、IDO1 和 PD-L1 表达及肿瘤免疫微环境的免疫组织化学分析。
Breast Cancer. 2023 Nov;30(6):1041-1053. doi: 10.1007/s12282-023-01498-7. Epub 2023 Aug 29.
本文引用的文献
1
Proteomic Landscape of Exosomes Reveals the Functional Contributions of CD151 in Triple-Negative Breast Cancer.外泌体的蛋白质组学全景揭示了 CD151 在三阴性乳腺癌中的功能贡献。
Mol Cell Proteomics. 2021;20:100121. doi: 10.1016/j.mcpro.2021.100121. Epub 2021 Jul 13.
2
CD151 enrichment in exosomes of luminal androgen receptor breast cancer cell line contributes to cell invasion.腔面雄激素受体乳腺癌细胞系外泌体中 CD151 的富集促进细胞侵袭。
Biochimie. 2021 Oct;189:65-75. doi: 10.1016/j.biochi.2021.06.007. Epub 2021 Jun 23.
3
Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.PIK3CA/AKT 突变在三阴性乳腺癌各分子亚型中的分布。
Breast Cancer Res Treat. 2021 Jun;187(3):625-633. doi: 10.1007/s10549-021-06242-3. Epub 2021 May 5.
4
Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women.老年女性三阴性乳腺癌的临床病理特征及预后标志物。
Hum Pathol. 2021 May;111:10-20. doi: 10.1016/j.humpath.2021.01.005. Epub 2021 Feb 3.
5
Quadruple-negative breast cancer: novel implications for a new disease.四阴性乳腺癌：一种新疾病的新意义。
Breast Cancer Res. 2020 Nov 19;22(1):127. doi: 10.1186/s13058-020-01369-5.
6
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies.三阴性乳腺癌的实用分类：瘤内异质性、耐药机制及新疗法
NPJ Breast Cancer. 2020 Oct 16;6:54. doi: 10.1038/s41523-020-00197-2. eCollection 2020.
7
Pathology of triple negative breast cancer.三阴性乳腺癌的病理学。
Semin Cancer Biol. 2021 Jul;72:136-145. doi: 10.1016/j.semcancer.2020.06.005. Epub 2020 Jun 13.
8
Ultrasonographic appearance of triple-negative invasive breast carcinoma is associated with novel molecular subtypes based on transcriptomic analysis.基于转录组分析，三阴性浸润性乳腺癌的超声表现与新的分子亚型相关。
Ann Transl Med. 2020 Apr;8(7):435. doi: 10.21037/atm.2020.03.204.
9
Histological subtypes in triple negative breast cancer are associated with specific information on survival.三阴性乳腺癌的组织学亚型与生存的具体信息相关。
Ann Diagn Pathol. 2020 Jun;46:151490. doi: 10.1016/j.anndiagpath.2020.151490. Epub 2020 Mar 3.
10
Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis.雄激素受体表达在三阴性乳腺癌中的预后意义：系统评价和荟萃分析。
Clin Breast Cancer. 2020 Aug;20(4):e385-e396. doi: 10.1016/j.clbc.2020.01.002. Epub 2020 Jan 18.
Zotero 插件